BAI Bing1, SANG Xiao-yu1, ZHOU Ya-pan1, YANG Na1, FENG Ying1, BAO Li2, LI Jiao2, DUAN Ping2, CHEN Qi-jun1, JIANG Ning1
1.Institute of Animal Husbandry and Veterinary Medicine of Shenyang Agricultural Uinversity,Shenyang 110866,China; 2.Liaoning Blood Center,Shenyang 110044,China
Abstract：Toxoplasma gondii is a serious foodborne zoonosis, which can not only affect the development of animal husbandry and the safety of meat products, but also cause great harm to public health. Therefore, the prevention of toxoplasmosis is crucial. Toxoplasma gondii vaccine which is regarded as an important measure to prevent toxoplasmosis has significant value to both public health and economics. This paper mainly summarizes advances in the study of Toxoplasma gondii vaccine in order to provide references for the further development of it, so as to control the toxoplasmosis more effectively.
[1] Zhang NZ, Wang M, Xu Y, et al. Recent advances in developing vaccines against Toxoplasma gondii : an update[J]. Expert Rev Vaccines, 2015, 14(12): 1609-1621. doi:10.1586/14760584.2015.1098539 [2] Liu Q, Wang ZD, Huang SY, et al. Diagnosis of toxoplasmosis and typing of Toxoplasma gondii [J].Parasit Vectors,2015,8(1):292.doi:10.1186/s13071-015-0902-6 [3] Cuchins EC, Warren J. Immunity patterns in the guinea pig following Toxoplasma infection and vaccination with killed Toxoplasma [J]. Am J Trop Med Hyg, 1956, 5(2): 197-209. doi:10.4269/ajtmh.1956.5.197 [4] Saavedra R, Leyva R, Tenorio EP, et al. CpG-containing ODN has a limited role in the protection against Toxoplasma gondii [J]. Parasite Immunol, 2004, 26(2): 67-73. doi:10.1111/j.0141-9838.2004.00684.x [5] Innes EA, Bartley PM, Maley S, et al. Veterinary vaccines against Toxoplasma gondii [J].Mem Inst oswaldo Cruz,2009,104(2):246-251.doi:10.1590/S0074-02762009000200018 [6] Buxton D. Toxoplasmosis: the first commercial vaccine[J]. Parasital Today, 1993, 9(9): 335-337. doi:10.1016/0169-4758(93)90236-9 [7] Montoya JG, Liesenfeld O. Toxoplasmosis[J]. Lancet, 2004, 363(9425): 1965-1976. doi:10.1016/S0140-6736(04)16412- [8] Katzer F, Canton G, Burrells A, et al. Immunization of lambs with the S48 strain of Toxoplasma gondii reduces tissue cyst burden following oral challenge with a complete strain of the parasite[J]. Vet Parasitol, 2014, 205(1-2): 46-56. doi:10.1016/j.vetpar.2014.07.003 [9] Burrells A, Benavides J, Cantón G, et al. Vaccination of pigs with the S48 strain of Toxoplasma gondii —safer meat for human consumption[J]. Vet Res, 2015, 46(1): 47. doi:10.1186/s13567-015-0177-0 [10] Fox BA, Bzik DJ. De novo pyrimidine biosynthesis is required for virulence of Toxoplasma gondii [J]. Nature, 2002, 415(6874): 926-929. doi:10.1038/415926a [11] Fox BA, Bzik DJ. Nonreplicating, cyst-defective type II Toxoplasma gondii vaccine strains stimulate protective immunity against acute and chronic infection[J]. Infect Immun, 2015, 83(5): 2148-2155. doi:10.1128/IAI.02756-14 [12] Abdelbaset AE, Fox BA, Karram MH, et al. Lactate dehydrogenase in Toxoplasma gondii controls virulence, bradyzoite differentiation, and chronic infection[J].PLoS One,2017,12(3):e0173745. doi:10.1371/journal.pone.0173745 [13] Fentress SJ, Steinfeldt T, Howard JC, et al. The arginine-rich N-terminal domain of ROP18 is necessary for vacuole targeting and virulence of Toxoplasma gondii [J]. Cell Microbiol, 2012, 14(12): 1921-1933. doi:10.1111/cmi.12022 [14] Grzybowski MM, Dziadek B, Dziadek J, et al. Toxoplasma gondii : cloning, expression and immunoreactivity of recombinant ROP5 and ROP18 antigens[J]. Exp Parasitol, 2015, 150: 1-6. doi:10.1016/j.exppara.2015.01.006 [15] Ching XT, Fong MY, Lau YL. Evaluation of immunoprotection conferred by the subunit vaccines of GRA2 and GRA5 against acute Toxoplasmosis in BALB/c mice[J]. Front Microbiol, 2016, 7(87): 609. doi:10.3389/fmicb.2016.00609 [16] Zhou QZ,Li M,Chen H,et al.Recombiant eukargotic plasmid of ROP16(Ⅰ/Ⅲ) faild to efficient against toxoplasmosis in BALB/c mice. [J]. Chin J Zoonoses, 2015,31(11):1010-1016. doi:10.3969/j.issn.1002-2694.2015.11.005(in Chinese) 周芹芝,李曼,陈鹤,等. 弓形虫ROP16_(Ⅰ/Ⅲ)DNA疫苗不能诱导小鼠有效的保护性免疫[J].中国人兽共患病学报,2015,31(11):1010-1016. [17] Wang S, Zhang Z, Wang Y, et al. Toxoplasma gondii elongation factor 1-alpha (TgEF-1a) is a novel vaccine candidate antigen against toxoplasmosis[J]. Front Microbiol, 2017, 8: 168. doi:10.3389/fmicb.2017.00168 [18] Lekutis C, Ferguson DJ, Grigg ME, et al. Surface antigens of Toxoplasma gondii : variations on a theme[J]. Int J Parasitol, 2001, 31(12): 1285-1292. doi:10.1016/S0020-7519(01)00261-2 [19] Zhang M, Zhao L, Song J, et al. DNA vaccine encoding the Toxoplasma gondii bradyzoite-specific surface antigens SAG2CDX protect BALB/c mice against type II parasite infection[J]. Vaccine, 2013, 31(41): 4536-4540. doi:10.1016/j.vaccine.2013.07.065 [20] Kawase O, Nishikawa Y, Bannai H, et al. Characterization of a novel thrombospondin-related protein in Toxoplasma gondii [J]. Parasitol Int, 2010, 59(2): 211-216. doi:10.1016/j.parint.2010.02.001 [21] Zheng B, Ding J, Chen X, et al. Immuno-efficacy of a T. gondii secreted protein with an altered thrombospondin repeat (TgSPATR) as a novel DNA vaccine candidate against acute Toxoplasmosis in BALB/c mice[J]. Front Microbiol, 2017, 8: 216. doi:10.3389/fmicb.2017.00216 [22] Hassan IA, Wang S, Xu L, et al. DNA vaccination with a gene encoding Toxoplasma gondii deoxyribose phosphate aldolase (TgDPA) induces partial protective immunity against lethal challenge in mice[J]. Parasit Vectors, 2014, 7(1): 431. doi:10.1186/1756-3305-7-431 [23] Dimier-Poisson I, Aline F, Bout D, et al. Induction of protective immunity against toxoplasmosis in mice by immunization with Toxoplasma gondii RNA[J]. Vaccine, 2006, 24(10): 1705-1709. doi:10.1016/j.vaccine.2005.09.053 [24] Chahl JS, Khan OF, Cooper CL, et al. Dendrimer-RNA nanoparticles generate protectivae immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose[J]. Proc Natl Acad Sci USA,2016, 113(29): E4133-4142. doi:10.1073/pnas.1612792113 [25] Leng J, Butcher BA, Denkers EY. Dysregulation of macrophage signal transduction by Toxoplasma gondii : past progress and recent advances[J]. Parasite Immunol,2009,31(12): 717-728. doi:10.1111/j.1365-3024.2009.01122.x [26] Henriquez FL, Woods S, Cong H, et al. Immunogenetics of Toxoplasma gondii informs vaccine design[J]. Trends Parasitol, 2010, 26(11): 550-555. doi:10.1016/j.pt.2010.06.004 [27] Cong H, Mui EJ, Witola WH, et al. Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8 + T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii [J]. Immunome Res, 2010, 6(1): 12. doi:10.1186/1745-7580-6-12
2017, Vol. 33 
